Charles River expands early discovery services

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/JK1991)
(Image: Getty/JK1991)
Charles River has upped to its early discovery capabilities with the addition of high-throughput technologies and expanded pharmacokinetic services.

According to Charles River, it is the first contract research organization (CRO) to provide clients access to Apricot Designs' Dual Arm (ADDA) system in North America and Europe.

Designed for drug discovery, the system is a high-speed autosampler for liquid chromatography/mass spectrometry (LC/MS).

“Apricot Designs’ dual arm autosampler was designed with early discovery scientists in mind,” ​said Felix H. Yiu, founder and CEO, Apricot Designs, Inc. in a press release. “It enables seamless integration with LC/MS systems, accelerating the laboratory research process and yielding the best results.”

Charles River has also geographically expanded its pharmacokinetic (PK) capabilities in San Francisco and 's-Hertogenbosch, The Netherlands.

“The early discovery industry is seeing a marked shift towards a better understanding of the underlying biology of candidate compounds. Both HT-ADME and PK technologies are critical to that understanding, and to developing more successful candidates in early discovery,”​ explained Ian Waddell, PhD, executive director, biology, Charles River.

Related news

Show more

Related products

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more